Extracorporeal light chain elimination: High cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury

Annals of Hematology

Volumn 91, Issue 5, 2012, Pages 729-735

  Heyne, Nils ^a   Denecke, Barbara ^a   Guthoff, Martina ^a   Oehrlein, Katharina ^a   Kanz, Lothar ^a   Häring, Hans Ulrich ^a   Weisel, Katja C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Acute kidney injury; HCO hemodialysis; Light chain elimination; Multiple myeloma; Renal recovery

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN LIGHT CHAIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALKALINIZATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; HYDRATION; IMMUNOASSAY; INTENSIVE CARE; KIDNEY BIOPSY; KIDNEY FUNCTION; LIGHT CHAIN; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SEPSIS; TREATMENT DURATION; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; PROGNOSIS; REFERENCE VALUE; STANDARD; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; REFERENCE VALUES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84861441771     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1383-0     Document Type: Review

References (38)

1. Alexanian R, Barlogie B, Dixon D (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 150:1693-1695 (Pubitemid 20240982)
2. Bladé J, Fernandez-Llama P, Bosch F, Montoliù J, Lens XM, Montoto S et al (1998) Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158:1889-1893 (Pubitemid 28440861)
3. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21-33 (Pubitemid 36033957)
4. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A et al (2007) Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 48:337-341 (Pubitemid 46994883)
5. Knudsen LM, Hjorth M, Hippe E (2000) Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 65:175-181
6. Torra R, Blade J, Cases A, López-Pedret J, Montserrat E, Rozman C et al (1995) Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 91:854-859
7. Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S et al (2009) Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 4:745-754
8. Santostefano M, Zanchelli F, Zaccaria A, Poletti G, Fusaroli M (2005) The ultrastructural basis of renal pathology in monoclonal gammopathies. J Nephrol 18:659-675 (Pubitemid 43085432)
9. Huang ZQ, Sanders PW (1995) Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Invest 73:810-817 (Pubitemid 26002340)
10. Ying WZ, Sanders PW (2001) Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 158:1859-1866 (Pubitemid 32422951)
11. Sanders PW, Booker BB, Bishop JB, Cheung HC (1990) Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest 85:570-576 (Pubitemid 20070067)
12. Sanders PW, Booker BB (1991) Pathobiology of cast nephropathy from human Bence Jones proteins. N Engl J Med 324:1845-1851
13. Blade J, Rosinol L (2005) Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol 18:635-652 (Pubitemid 40984119)
14. Basnayake K, Cheung CK, Sheaff M, Fuggle W, Kamel D, Nakoinz S et al (2010) Differential progression of renal scarring and determinants of late recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. J Clin Pathol 63:884-887
15. Tsakiris DJ, Stel VS, Finne P, Fraser E, Heaf J, de Meester J et al (2010) Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or lightchain deposit disease: an ERA-EDTA Registry Study. Nephrol Dial Transplant 25:1200-1206
16. Richardson PG, Barlogie B, Berenson J, Shingal S, Jagannath S, Irwin DH, SUMMIT Investigators et al (2005) Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 106:2977-2981 (Pubitemid 41565888)
17. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al (2010) Lenalidomide plus high-dose dexamathasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29-37
18. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28:4976-4984
19. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE (1990) Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis and chemotherapy. Arch Intern Med 150:863-869 (Pubitemid 20122064)
20. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barret BJ et al (2005) Plasma exchange when myeloma presents as acute renal failure: a randomized controlled trial. Ann Intern Med 143:777-784
21. Weisel KC, Heyne N, Hutchison CA, Göhl H, Risler T, Kanz L (2007) Effective light chain elimination via a high cut-off protein permeable filter in patients with light chain myeloma disease. Onkologie 30(suppl 3):80
22. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J et al (2007) Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 18:886-895 (Pubitemid 46434505)
23. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit Care 8:R204-R212
24. Mehta RL, Kellum JA, Shah SV (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31
25. Verfoord G, Willems HL, Wetzels JF (2002) Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 17:1909-1913 (Pubitemid 35277086)
26. Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Mikou M, Matsuoka C et al (2009) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens. Clin Lymphoma Myeloma 9:302-306
27. Kidney Disease Outcomes Quality Initiative (K/DOQI) (2002) Executive summary. Am J Kidney Dis 39(suppl 1):S17-S31
28. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, International Myeloma Working Group et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473 (Pubitemid 44264086)
29. Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485-1493
30. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S et al (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109:2604-2606 (Pubitemid 46425908)
31. Ludwig H, Drach J, Graf H, Lang A, Meran JG (2007) Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 92:1411-1414 (Pubitemid 350144160)
32. Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F et al (2010) Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 28:4635-4641
33. Dimopoulos MA, Christoulas D, RoussouM, Kastritis E, Anagnostou D, Koureas A et al (2010) Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 85:1-5
34. Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM et al (2010) The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 116:3807-3814
35. Matsue K, Fujiwara H, Iwama KI, Kimura S, Yamakura M, Takeuchi M (2010) Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. Ann Hematol 89:291-297
36. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsuoka C, Barmparousi D et al (2007) Reversibility of acute renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone containing regimens and the impact of novel agents. Haematologica 92:546-549 (Pubitemid 350144300)
37. Wynckel A, Vuiblet V, Schneider N, Kolb B, Melin JP, Journet J et al (2010) Comparison of plasma exchange and hemodialysis using a high cut-off membrane (HCO) for removal of immunoglobulin free light chains in multiple myeloma. J Am Soc Nephrol 21:39A
38. Hutchison CA, Cook M, Heyne N, Weisel KC, Billingham L, Bradwell A et al (2008) European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE). A randomised control trial. Trials 9:55